lanadelumab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
lanadelumab: clinical details
Prescribing considerations
- Initiate under a clinician experienced in hereditary angioedema management.
- Do not replace access to an approved breakthrough-attack treatment and plan.
- Evidence is limited in hereditary angioedema with normal C1 inhibitor; consider the underlying genetic pathway and assess response carefully.
- Record the product name and batch number for traceability.
- Ensure the patient or caregiver understands administration, storage, inspection and sharps disposal.
Contraindications and cautions
- Hypersensitivity to lanadelumab or any formulation excipient.
Monitoring
- Review attack frequency, severity, rescue-treatment use and clinical response.
- Assess injection-site reactions and hypersensitivity symptoms.
- Routine laboratory monitoring is not specified; consider liver testing when clinically indicated because aminotransferase increases have been reported.
- Lanadelumab can prolong activated partial thromboplastin time through assay interference without corresponding abnormal bleeding; interpret an isolated prolonged result in context.
Clinical pharmacology
A fully human IgG1 monoclonal antibody that inhibits active plasma kallikrein, reducing high-molecular-weight kininogen cleavage and bradykinin generation. Elimination is mainly through intracellular antibody catabolism.
Formulation and product differences
- Ready-to-use, single-use pre-filled syringe with a fixed needle.
- The solution should be clear or slightly opalescent and colourless to slightly yellow; do not shake it.
- Keep refrigerated and protected from light. It may be kept below 25°C for one permitted room-temperature period stated in the product information and must not then be returned to the refrigerator.
lanadelumab preparations and strengths
Injection
Route: Parenteral
Strengths: 150 mg, 300 mg
lanadelumab interactions
Clinically important pharmacokinetic interactions are not expected, although dedicated interaction studies have not been performed.
C1 esterase inhibitor rescue treatment
Concurrent use produces an expected additive effect on kallikrein-pathway biomarkers. Use rescue treatment according to the established attack plan.
Other medicines
Tell the specialist about all prescribed, over-the-counter and complementary products.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.